Seprafilm Adhesion Barrier
Meticulous surgical technique alone may not be enough to prevent adhesion formation. Seprafilm Adhesion Barrier significantly reduces the incidence, extent and severity of adhesions following abdominopelvic laparotomy surgery.1,2
Explore this Product
Overview
Mechanism of Action
Seprafilm Adhesion Barrier is a sterile, bioresorbable, translucent and hydrophilic adhesion barrier. It is composed of two anionic polysaccharides: modified sodium hyaluronate and carboxymethylcellulose (HA/CMC).1
Adhesions are not preventable by surgical technique alone
Adhesions develop routinely following both open and laparoscopic* abdominal surgery and have been reported at second-look surgery to occur in up to 93% of patients (n=210) following one or more open abdominal operations.3
*Seprafilm Adhesion Barrier is not indicated in laparoscopic surgery.
Learn about Adept Adhesion Reduction Solution use in laparoscopic surgery
The Clinical and Economic Burden of Adhesions is Extensive
Adhesions are a major cause of small bowel obstruction, infertility and chronic pelvic pain and can complicate future surgery, with annual surgical costs of more than $2 billion in the U.S.4,5
Seprafilm Adhesion Barrier Efficacy in Abdominal Surgery
In a randomized, prospective, double-blinded, multicenter clinical study involving 183 patients [175 evaluable] with ulcerative colitis and familiar polyposis undergoing 2-stage intestinal resection, 51% of the Seprafilm Adhesion Barrier group were adhesion-free at 8-12 weeks compared to 6% of control patients.2
SEPRAFILM Adhesion Barrier is the only adhesion prevention product approved in the U.S. for abdominal open procedures.6
Seprafilm Adhesion Barrier Efficacy in Pelvic Surgery
In a prospective, randomized, blinded, multicenter clinical study involving 127 patients undergoing gynecologic surgery, Seprafilm Adhesion Barrier reduced the mean number of sites adherent to the uterine surface following myomectomy compared with untreated patients. Seprafilm also significantly reduced the extent and severity of adhesions in patients undergoing uterine myomectomy compared with untreated patients.7
Features
Additional Product Benefits
Protection When it Matters Most
Separates tissues for up to seven days—the critical tissue healing period.1
A Proven Legacy
More than 4 million patients have received Seprafilm Adhesion Barrier in clinical use worldwide.8 Robust clinical trials (n=2,133) across five clinical studies resulted in Seprafilm Adhesion Barrier significantly reducing the incidence, extent, and severity following abdominopelvic laparotomy surgery.1,8
Bioresorbable and Synthetic
Seprafilm Adhesion Barrier is composed of sodium hyaluronate and carboxymethylcellulose (HA/CMC).1
Order & Support
Learn More about Seprafilm Adhesion Barrier
Ordering and Support Information for Seprafilm Adhesion Barrier
Get additional ordering, customer, technical, and medical support information for Seprafilm Adhesion Barrier by contacting Baxter using the links below.
U.S. Catalog
To buy this product or look for options and specs please visit U.S. Catalog.
U.S. Support
For manuals and documentation, product training, technical support and services, submit repair and return requests or check order status for Hillrom, Allen Medical and Welch Allyn product please visit U.S. Support.
U.S. Edu
For medical information or non-promotional education about our products or therapies, please visit U.S. Edu.
Contact Us
To find contact details and assistance for Baxter products, report an adverse event or report a product complaint, or any other inquiries, please visit our contact us page.
Are You Interested in Additional Information about Seprafilm?
Resources
All Resources for Seprafilm Adhesion Barrier
What is Seprafilm Adhesion Barrier?
The field of medicine, and more specifically surgery, is one that is continuously evolving with every advancement in technology and biotechnology. One significant milestone in the realm of surgical interventions is the development of bioresorbable adhesion barriers.
More Products
Other Information
Seprafilm Indications and Important Risk Information
SEPRAFILM Indications for Use
Seprafilm Adhesion Barrier is indicated for use in patients undergoing abdominal or pelvic laparotomy as an adjunct intended to reduce the incidence, extent and severity of postoperative adhesions between the abdominal wall and the underlying viscera such as omentum, small bowel, bladder and stomach, and between the uterus and surrounding structures such as tubes and ovaries, large bowel and bladder.
SEPRAFILM Important Risk Information
- Seprafilm Adhesion Barrier is contraindicated in patients with a history of hypersensitivity to Seprafilm and/or to any component of Seprafilm. Seprafilm Adhesion Barrier is contraindicated for use wrapped directly around a fresh anastomotic suture or staple line; as such use increases the risk of anastomotic leak and related events (fistula, abscess, leak, sepsis, peritonitis). Seprafilm Adhesion Barrier must be used according to the instructions for use. Seprafilm Adhesion Barrier is for single use only, supplied sterile and must not be re-sterilized. Every opened and unused Seprafilm pouch must be discarded. Do not use product if pouch is damaged or opened. The number of sheets used should be just adequate to cover the under surface of the abdominal wall or uterine incision in a single layer.
In patients who have ovarian, primary peritoneal or fallopian tube malignancies, Seprafilm use has been reported to have an increased risk of intra-abdominal fluid collection and/or abscess, particularly when extensive debulking surgery was required.
The safety and effectiveness of Seprafilm Adhesion Barrier has not been evaluated in clinical studies for the following: Patients with frank infections in the abdominopelvic cavity; patients with abdominopelvic malignancy; device placement in locations other than directly beneath an abdominal wall incision following laparotomy, or directly on the uterus following open myomectomy (not laparoscopic); patients with ongoing local and/or systemic inflammatory cell responses; device use in the presence of other implants, e.g. surgical mesh; patients requiring re-operation within four weeks of Seprafilm placement – during anticipated time of peak adhesion formation. Foreign body reactions have occurred with Seprafilm Adhesion Barrier.
The safety and effectiveness of Seprafilm Adhesion Barrier in combination with other adhesion prevention products and/or in other surgical procedures not within the abdominopelvic cavity have not been established in clinical studies.
The safe and effective use of Seprafilm Adhesion Barrier in pregnancy and Cesarean section has not been evaluated. No clinical studies have been conducted in pregnant women or women who have become pregnant within the first month after exposure to Seprafilm Adhesion Barrier. Therefore, this product is not recommended for use during pregnancy and avoidance of conception should be considered during the first complete menstrual cycle after use of Seprafilm Adhesion Barrier.
Long term clinical outcomes such as chronic pain and infertility have not been determined in clinical studies.
Rx Only. For safe and proper use of this device refer to the complete Instructions for Use.
Disclaimers
*Seprafilm Adhesion Barrier is not indicated in laparoscopic surgery.
For safe and proper use of product mentioned herein, please refer to the Instructions for Use or Operator Manual.
Baxter, Adept, Coseal, Floseal and Seprafilm are trademarks of Baxter International Inc. or its subsidiaries. Any other trademarks, product names or brand images are the property of their respective owners.
References
- SEPRAFILM Adhesion Barrier Instructions for Use.
- Becker JM, Dayton MT, Fazio VW, et al. Prevention of postoperative abdominal adhesions by a sodium hyaluronate-based bioresorbable membrane: a prospective, randomized, double-blind multicenter study. J Am Coll Surg. 1996;183(4):297-306.
- Menzies D, Ellis H. Intestinal obstruction from adhesions—how big is the problem? Ann R Coll Surg Engl. 1990;72(1):60-63.
- Bruggmann 0, Tchartchian G, Wallwiener M, Munstedt K, Tinneberg HR, Hackethal A. Intra-abdominal adhesions. Dtsch Arztebl Int. 2010;107(44):769-775.
- Sikirica V, et al. BMC Surg 2011; 11: 13.
- GYNECARE INTERCEED Barrier IFU.
- Diamond MP. Seprafilm Adhesion Study Group. Reduction of adhesions after uterine myomectomy by Seprafilm membrane (HAL-F): a blinded, prospective, randomized, multicenter clinical study. Fertil Steril. 1996;66(6):904-910.
- SEPRAFILM Product Monograph. 2016. Baxter. [Data on file]. REF-27637.